Research Analysts’ Recent Ratings Updates for DBV Technologies (DBVT)

A number of firms have modified their ratings and price targets on shares of DBV Technologies (NASDAQ: DBVT) recently:

• 12/29/2025 – DBV Technologies had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – DBV Technologies had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/18/2025 – DBV Technologies was given a new $40.00 price target on by analysts at HC Wainwright.
• 12/17/2025 – DBV Technologies was given a new $48.00 price target on by analysts at Cantor Fitzgerald.
• 12/17/2025 – DBV Technologies had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 12/17/2025 – DBV Technologies had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $51.00 price target on the stock, up previously from $35.00.
• 12/17/2025 – DBV Technologies had its price target raised by analysts at Citizens Jmp from $21.00 to $45.00. They now have a “market outperform” rating on the stock.
• 12/15/2025 – DBV Technologies had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock, up previously from $20.00.
• 12/15/2025 – DBV Technologies was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating.
• 12/14/2025 – DBV Technologies is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $42.00 price target on the stock.
• 12/8/2025 – DBV Technologies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/3/2025 – DBV Technologies is now covered by analysts at Guggenheim. They set a “buy” rating and a $35.00 price target on the stock.
• 12/3/2025 – DBV Technologies is now covered by analysts at Guggenheim. They set a “buy” rating and a $35.00 price target on the stock.
• 12/1/2025 – DBV Technologies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/28/2025 – DBV Technologies was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/25/2025 – DBV Technologies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – DBV Technologies had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

Insider Buying and Selling

In other DBV Technologies news, major shareholder Bpifrance Epic sold 1,292,103 shares of the stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $4.19, for a total value of $5,413,911.57. Following the transaction, the insider owned 7,303,369 shares of the company’s stock, valued at approximately $30,601,116.11. This represents a 15.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.44% of the company’s stock.

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.